Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Provided By GlobeNewswire
Last update: Nov 12, 2025
PDUFA Target Date of December 13, 2025 for CARDAMYST™ (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT)
Promotional Launch Plans Set with Quick-Start Capability Upon Potential FDA Approval
Read more at globenewswire.com2.15
+0.07 (+3.37%)
Find more stocks in the Stock Screener
MIST Latest News and Analysis
